Prime Medicine, Inc. (PRME) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-102.2%

-$0.10

vs $4.44 price

Levered DCF

-$0.44

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-5.36

Distress zone

Rating

D+

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-2.57×	-1.77×	-4.07×	-12.72×	-7.99×	-291.1×	-526.37×
P/B	4.27×	2.26×	6.06×	5.71×	6.14×	43.96×	1,059.3×
P/S	111.44×	116.1×	0×	0×	0×	282.41×	0×
EV / EBITDA	-2.91×	-1.08×	-4.17×	-13.67×	-7.84×	-1,613.5×	366.51×
Gross margin	-58.1%	100.0%	0.0%	0.0%	0.0%	42.8%	0.0%
Operating margin	-4498.1%	-6787.4%	0.0%	0.0%	0.0%	-17.9%	0.0%
Net margin	-4342.4%	-6566.6%	0.0%	0.0%	0.0%	-65.5%	0.0%
Current ratio	4.84×	5.58×	2.53×	11.1×	4.67×	2.75×	1.19×
Debt / equity	0.96×	0.27×	0.1×	0.09×	0.04×	0×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-166.4%	-127.9%	-148.9%	-38.5%	-69.0%	-10.2%	-182.1%
Return on invested capital	-66.5%	-76.9%	-139.4%	-33.5%	-33.5%	-2.6%	-156.4%
Return on assets	-58.7%	-65.8%	-102.2%	-33.8%	-54.8%	-6.2%	-29.1%
Free cash flow yield	-32.4%	-37.6%	-21.6%	-8.2%	-2.6%	-0.4%	-0.1%
Earnings yield	-39.0%	-56.6%	-24.6%	-6.7%	-11.2%	-0.2%	-0.2%
Enterprise value	$569.6M	$204.6M	$778M	$1.6B	$1.3B	$1.4B	$1.5B
Net debt / EBITDA	-0.27×	0.75×	0.15×	1.32×	1.06×	41.59×	-2.17×
Cash conversion cycle (days)	-443	0	0	0	0	-31	0